title: Fas and Fas ligand interactions in malignant disease.
abstract: Apoptosis has been implicated in tumor development and progression. Fas (CD95) and Fas ligand (FasL) are an interacting receptor ligand pair that elicits apoptosis in many cell types. Although originally described as proteins regulating peripheral immune tolerance, accumulating evidence suggests that Fas/FasL may play an important role in carcinogenesis, tumor outgrowth, and metastasis. This review summarizes our current knowledge about the regulation of Fas and FasL expression, Fas signaling, soluble Fas production, the role(s) of Fas and FasL in hematopoietic and non-hematopoietic tumorigenesis and progression, and the potential application of Fas-induced apoptosis in cancer therapy.
authors.affiliation: Department of Immunology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
authors.forename: L
authors.initials: L
authors.lastname: Owen-Schaub
authors.forename: H
authors.initials: H
authors.lastname: Chan
authors.forename: J C
authors.initials: JC
authors.lastname: Cusack
authors.forename: J
authors.initials: J
authors.lastname: Roth
authors.forename: L L
authors.initials: LL
authors.lastname: Hill
mesh_terms: D000818:Animals; D017209:Apoptosis; D053222:Fas Ligand Protein; D015316:Genetic Therapy; D006801:Humans; D008562:Membrane Glycoproteins / Q000502:physiology*; D009369:Neoplasms / Q000473:pathology* / Q000503:physiopathology*; D019014:fas Receptor / Q000502:physiology*
chemical_list: C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins; D019014:fas Receptor